16 September 2003 11:28 [Source: ICIS news]
LONDON (CNI)--UK biotechnology firm Scynexis Europe has expanded its pharmaceuticals research and development (R&D) agreement with Swiss drugs company Roche.
In a statement received Tuesday, the UK firm said that the R&D pact had been broadened in scope and duration. The companies have been collaborating to develop novel compounds to treat central nervous system disorders and metabolic diseases.
Financial terms of the expanded deal were not disclosed. Scynexis said, though, that the collaboration would give Roche access to its Medchem-Factory technology and Heos Hit Explorer operating system software, which it added should help to accelerate the identification of candidate compounds.
Under the agreement, Roche receives exclusive worldwide rights to products developed through the R&D pact with Scynexis. In return, the UK firm will receive technology access fees and other, unspecified, payments.
Scynexis Europe is part of US group Scynexis.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
|ICIS news FREE TRIAL|
|Get access to breaking chemical news as it happens.|
|ICIS Global Petrochemical Index (IPEX)|
|ICIS Global Petrochemical Index (IPEX). Download the free tabular data and a chart of the historical index|